Antibiotic drug developers and infectious disease specialists are pushing for immediate enactment of legislation to carve-out new antibiotics from inpatient payments to help preserve the pipeline of new therapies while longer term solutions are debated.
“The time to kick the can down the road has passed,” Antimicrobials Working Group representative Jeff Stein (CEO of







